Yue Xiang Yue Health Submits IPO Filing in February 2026
Noliving Biotech
Innovative High-End Medical Device R&D and Manufacturer
Slate Medicines
Developer of Migraine and Other Headache Disorder Therapeutics
Trinomab
Developer of Natural Fully Human Monoclonal Antibody New Drugs
Century Healthcare
Medical Device Manufacturer, R&D, and Distributor
Healthgen Biotech
Research and Product Developer of Plant-derived Recombinant Protein Expression Technology
With the spring breeze blowing vigorously, we spur our horses forward. Riding on the momentum of the 2026 Year of the Horse Spring Festival, YF Capital has been announcing good news this month:NorthX Life Successfully Listed on the STAR Market; Three Portfolio Companies Progress SimultaneouslyAll HKEX IPO applications have been accepted.
At the same time, more invested companies are making breakthroughs in multiple key areas and advancing on all fronts, rapidly writing a new chapter for China's biopharmaceutical industry with vigorous momentum.
01
Progress of Portfolio Companies' IPOs and Financing
NorthX Biotech
· NorthX Life Successfully Listed on the STAR Market
NorthX Biotech
· NorthX Life Successfully Listed on the STAR Market
On February 5, NorthX Life successfully listed on the STAR Market of the Shanghai Stock Exchange, with an issue price of RMB 17.52 per share.
On February 5, NorthX Life successfully listed on the STAR Market of the Shanghai Stock Exchange, with an issue price of RMB 17.52 per share.
Bonacia
· Bonacia Submits Application to HKEX
Bonacia
· Bonacia Submits Application to HKEX
Pulai Pharmaceuticals
· Pulai Pharmaceuticals Submits Listing Application to HKEX
Pulai Pharmaceuticals
· Pulai Pharmaceuticals Submits Listing Application to HKEX
On February 13, Pule Pharmaceutical submitted an application for listing on the Main Board of the Hong Kong Stock Exchange.
On February 13, Pule Pharmaceutical submitted an application for listing on the Main Board of the Hong Kong Stock Exchange.
Noliving Biotech
· Noliving Biotech Charges Towards HKEX IPO
Noliving Biotech
· Noliving Biotech Charges Towards HKEX IPO
On February 13, Noliving Biotech officially submitted its A1 prospectus to the Hong Kong Stock Exchange. The Hong Kong stock market is expected to welcome the first "hardcore" technology company in the nitric oxide (NO) diagnosis and treatment sector.
On February 13, Noliving Biotech officially submitted its A1 prospectus to the Hong Kong Stock Exchange. The Hong Kong stock market is expected to welcome the first "hardcore" technology company in the nitric oxide (NO) diagnosis and treatment sector.
02
Clinical and Commercial Dynamics of Invested Companies
Dashi Pharmaceutical
· Enter into a Licensing Collaboration with Slate Medicines
Dashi Pharmaceutical
· Enter into a Licensing Collaboration with Slate Medicines
Recently, Dashi Pharmaceutical announced that it has entered into an exclusive licensing agreement with Slate Medicines. Under the agreement, Dashi Pharmaceutical will grant Slate Medicines the exclusive global rights (excluding Greater China) for the clinical development and commercialization of DS009, a potential best-in-class monoclonal antibody targeting Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP), for the preventive treatment of migraine and other headache disorders.
Trinomab
· RSVMonoclonal Antibody Proposed for Priority Review
Trinomab
· RSVMonoclonal Antibody Proposed for Priority Review
On February 9, Trinomab's Rietuvab monoclonal antibody was submitted for marketing authorization in China, intended for the prevention of lower respiratory tract infections (LRTI) caused by Respiratory Syncytial Virus (RSV) in infants under 1 year of age (including high-risk populations susceptible to severe RSV infection).
Century Healthcare
· Century Healthcare Successfully Applied in Major Hospitals
Century Healthcare
· Century Healthcare Successfully Applied in Major Hospitals
Recently, the First Affiliated Hospital of Guangzhou Medical University、Renmin Hospital of Wuhan UniversitySuccessful ApplicationLumisight®TrifocalPlusIntraocular Lens, VisionEase®Ultra-EDoFIntraocular Lens。
Kaiser Biotech
· Debut at the SLAS2026 International Conference and Exhibition in the United States
Recently, Healthgen BiotechHealthgen Biotech Attends SLAS2026 International Conference and Exhibition in the U.S., Engaging in Multiple Heated and Fruitful Discussions with Global Academia-Industry Colleagues on Industry Trends, Technological Breakthroughs, and Collaboration Opportunities.
Kaiser Biotech
· Debut at the SLAS2026 International Conference and Exhibition in the United States
Recently, Healthgen BiotechHealthgen Biotech Attends SLAS2026 International Conference and Exhibition in the U.S., Engaging in Multiple Heated and Fruitful Discussions with Global Academia-Industry Colleagues on Industry Trends, Technological Breakthroughs, and Collaboration Opportunities.
Biolnov
· Debut at WHX Dubai 2026
In February, the global healthcare industry event WHX Dubai was officially held in the UAE. Bioinno BiotechCDMOService system, serum-free culture technology platform, and regenerative medicine solutions debut at this exhibition.
Biolnov
· Debut at WHX Dubai 2026
In February, the global healthcare industry event WHX Dubai was officially held in the UAE. Bioinno BiotechCDMOService system, serum-free culture technology platform, and regenerative medicine solutions debut at this exhibition.
Healthgen Biotech
· Aofumin® Phase IV Real-World Study Protocol Receives CDE Public Disclosure
Healthgen Biotech
· Aofumin® Phase IV Real-World Study Protocol Receives CDE Public Disclosure
On February 25, the National Medical Products Administration's Drug Clinical Trial Registration and Information Disclosure Platform released an information disclosure, stating that Healthgen Biotech's Aofumin®—Recombinant Human Albumin Injection (Rice) has launched a Phase IV real-world study in patients with hypoalbuminemia and/or insufficient blood volume requiring emergency treatment.
On February 25, the National Medical Products Administration's Drug Clinical Trial Registration and Information Disclosure Platform released an information disclosure, stating that Healthgen Biotech's Aofumin®—Recombinant Human Albumin Injection (Rice) has launched a Phase IV real-world study in patients with hypoalbuminemia and/or insufficient blood volume requiring emergency treatment.
03
Approval Status of New Drugs and Medical Devices from Invested Companies
Trinomab
· Milestone for China-produced Anti-RSV Monoclonal Antibody: NDA of Retwevirumab Injection Accepted
Trinomab
· Milestone for China-produced Anti-RSV Monoclonal Antibody: NDA of Retwevirumab Injection Accepted
On February 13, Trinomab's new drug application (NDA) for the recombinant long-acting anti-respiratory syncytial virus (RSV) fully human monoclonal antibody — Riatuvirumab Injection — was officially accepted by the National Medical Products Administration.
On February 13, Trinomab's new drug application (NDA) for the recombinant long-acting anti-respiratory syncytial virus (RSV) fully human monoclonal antibody — Riatuvirumab Injection — was officially accepted by the National Medical Products Administration.
3D Medicines
· Envada's Conditional Approval Conversion to Full Approval Supplemental Application Officially Accepted by NMPA
3D Medicines
· Envada's Conditional Approval Conversion to Full Approval Supplemental Application Officially Accepted by NMPA
In February, 3D Medicines announced that the supplemental application for the domestically produced drug Envada®—which transitioned from conditional approval to full approval—was officially accepted by the National Medical Products Administration (NMPA).
In February, 3D Medicines announced that the supplemental application for the domestically produced drug Envada®—which transitioned from conditional approval to full approval—was officially accepted by the National Medical Products Administration (NMPA).
04
Honors of Invested Enterprises
Selected2025“Highly Cited Chinese Scholars"List
· Dr. Shi Fu Chen, Founder and CTO of HaploX
Selected2025“Highly Cited Chinese Scholars"List
· Dr. Shi Fu Chen, Founder and CTO of HaploX
Amepharma Awarded "Best Partner"
· Tianqin Biotech
Amepharma Awarded "Best Partner"
· Tianqin Biotech
AwardedThe First Batch of Key Cultivated Enterprises in Hefei Economic and Technological Development Zone Enterprise Cultivation Center Awarded
2025 Hefei Economic and Technological Development Zone "Sci-Tech Innovation Star Enterprise Award"
· Tiangang Medinno
AwardedThe First Batch of Key Cultivated Enterprises in Hefei Economic and Technological Development Zone Enterprise Cultivation Center Awarded
2025 Hefei Economic and Technological Development Zone "Sci-Tech Innovation Star Enterprise Award"
· Tiangang Medinno
AwardedZhejiang Provincial Science and Technology Progress Award
· Nurotron
05
Yifeng Honor
▷ Economic Observer
Yifeng Capital-
"New Quality 100" Investment Institutions List
▷ Titanium Media
Zhu Pai-
Top 20 Young Venture Capitalists of 2025
AwardedZhejiang Provincial Science and Technology Progress Award
· Nurotron
05
Yifeng Honor
▷ Economic Observer
Yifeng Capital-
"New Quality 100" Investment Institutions List
▷ Titanium Media
Zhu Pai-
Top 20 Young Venture Capitalists of 2025